New River reiterated at buy by Merrill

Merrill Lynch analyst David Munno reiterated New River Pharmaceuticals Inc. at a buy following Shire's and Barr's settled patent litigation surrounding Adderall XR, NRP104's soon-to-be predecessor. Barr is prevented from launching a generic version of Adderall XR until April 1, 2009, giving New River and Shire more than two years to transition patients to NRP104 from Adderall XR. Shares of the Radford, Va.-based pharmaceutical company were up $3.17, or 13.76%, at $26.20, on volume of 1,514,983 shares versus the three-month running average of 338,217 shares. (Nasdaq: NRPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.